Latest Global Markets News

Golden Deeps Ltd reports exceptional high-grade copper, silver, zinc, and germanium results from its Graceland Prospect in Namibia, setting the stage for targeted drilling of Tsumeb-style deposits.

Vanguard Investments Australia has announced estimated distribution amounts and a clear timetable for over 20 of its Australian-listed ETFs, with payments scheduled for mid-October 2025.

Victory Metals has taken a significant step forward by signing a non-binding Letter of Intent with Sumitomo Corporation to supply heavy rare earths from its North Stanmore project, marking a deepening of their strategic partnership.

Nova Eye Medical has gained regulatory approval for its iTrack Advance glaucoma device in China, setting the stage for significant market expansion and sales growth from late fiscal 2026.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

The Calmer Co. has secured $700,000 in the first tranche of a $1.4 million convertible note raise, welcoming US distributor Applied Food Sciences as a strategic investor to fuel its expanding wholesale presence.

INOVIQ Limited has obtained exclusive worldwide rights to novel ovarian cancer biomarker IP from UniQuest, propelling its EXO-OC™ test closer to commercial launch. The test’s exceptional sensitivity and specificity position it as a potential breakthrough in early cancer detection.

Premier Investments reported a 31.1% rise in net profit after tax for FY25, driven by strong growth in its continuing operations after divesting its Apparel Brands to Myer. The company is now concentrating on expanding its high-margin Peter Alexander and Smiggle brands.

EMVision Medical Devices has initiated a unique pre-hospital study in Melbourne to test its First Responder Brain Scanner within one of the world’s few Mobile Stroke Units, aiming to enhance stroke diagnosis and accelerate commercialisation.

Clover Corporation posted a robust 38% revenue increase to $86 million in FY25, driven by product innovation and operational gains, while declaring a final dividend. The company’s cautious outlook for FY26 reflects ongoing regulatory and production challenges.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

Resimac Group has successfully settled a A$1 billion non-conforming residential mortgage backed securities transaction, marking its second such bond issuance this year. The deal attracted strong domestic and offshore investor interest, reinforcing Resimac’s diversified funding strategy.